Cytogenetic markers in hematoproliferative disorders.
In the last decade the improvement of methods of chromosome analysis has allowed new insights into the correlation of specific chromosome changes and certain types of malignant hematologic disorders. Even if a clear-cut correlation between a certain chromosomal marker and a certain malignancy is the exception, it is well established that specific chromosome aberrations occur nonrandomly in specific tumors. Moreover, it has been shown that so-called cellular oncogenes are located on those chromosome regions which are involved in translocations and other structural chromosome abnormalities in particular malignant tumors. The significance of chromosome alterations in leukemias and lymphomas is illustrated by examples concerning well-established data, on the one hand, and findings which have still to be confirmed, on the other. This may demonstrate that human tumor cytogenetics are a dynamically and vigorously developing branch of cancer research.
D001853:Bone Marrow / Q000473:pathology; D001855:Bone Marrow Diseases / Q000235:genetics; D002869:Chromosome Aberrations / Q000150:complications; D002871:Chromosome Banding; D025063:Chromosome Disorders; D003582:Cytogenetics; D064420:Drug-Related Side Effects and Adverse Reactions; D005819:Genetic Markers; D005826:Genetics, Medical / Q000639:trends; D006801:Humans; D007621:Karyotyping; D007938:Leukemia / Q000139:chemically induced / Q000175:diagnosis; D008232:Lymphoproliferative Disorders / Q000235:genetics; D009196:Myeloproliferative Disorders / Q000235:genetics*; D009367:Neoplasm Staging; D011379:Prognosis
D005819:Genetic Markers